恆瑞醫藥(600276.SH):硫酸艾瑪昔替尼片獲得藥品註冊批準
格隆匯6月30日丨恆瑞醫藥(600276.SH)公佈,公司收到國家藥品監督管理局的通知,批準公司自主研發的1類創新藥硫酸艾瑪昔替尼片(SHR0302片)新增適應症,用於成人重度斑禿患者。
硫酸艾瑪昔替尼片是一種高選擇性的JAK1抑制劑,可通過抑制JAK1信號傳導發揮抗炎和抑制免疫的生物學效應。該產品已在國內獲批上市三個適應症,分別爲:用於對一種或多種TNF抑制劑療效不佳或不耐受的活動性強直性脊柱炎成人患者;用於對一種或多種TNF抑制劑療效不佳或不耐受的中重度活動性類風溼關節炎成人患者;用於對局部外用治療或其他系統性治療應答不充分或不耐受的中重度特應性皮炎成人患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.